AI Insight
The U.S. Food and Drug Administration has approved Hepcludex (bulevirtide-gmod) injection as the first treatment for chronic hepatitis delta virus (HDV) infection in adults. The approval applies to patients without cirrhosis or those with compensated cirrhosis, and was granted to Gilead Sciences.
Why it matters
This represents a significant medical breakthrough as it provides the first FDA-approved treatment option for chronic HDV infection, which is considered one of the most severe forms of viral hepatitis. The approval offers a new therapeutic avenue for patients who previously had limited treatment options for this serious liver disease.
Understand the Science
The U.S. Food and Drug Administration has approved Hepcludex (bulevirtide‐gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or compensated cirrhosis. Approval of Hepcludex was granted to Gilead Sciences.
Source: FDA approves first treatment for chronic hepatitis delta virus infection